

A REVIEW ON UTERINE FIBROIDS - CAUSES, PATHOGENESIS, DIAGNOSIS, AND MANAGEMENT

Pratiksha Raman Kabde^{1*}, Harshdeep Sunil Sapkal², Shrimangale Ayodhya Ramesh³, Gauri Vitthal Chavale⁴, Syeda Adiba Fatima Syed Ashfaque Ahmed⁵

^{1,2,3,4,5} Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.



*Corresponding Author: Pratiksha Raman Kabde

Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

Email ID: pratikshakabde@gmail.com

Article Received on 31/05/2024

Article Revised on 21/06/2024

Article Accepted on 11/07/2024

ABSTRACT

Among women of reproductive age, uterine fibroids—also referred to as leiomyomas or myomas—are often occurring benign tumors. The precise cause of fibroids is still unknown despite their widespread occurrence, however growth factors, hormone abnormalities, and heredity all play important parts. This review thoroughly investigates the etiology and pathophysiology of uterine fibroids, looking at the underlying molecular pathways and genetic predispositions. To give a thorough picture of contemporary methods, diagnostic tools, such as imaging techniques and histological examination, are addressed. Furthermore, the study emphasizes different approaches to management, from medication therapies to surgical procedures, emphasizing new developments and potential paths for the profession. This review attempts to provide a comprehensive overview of uterine fibroids and assist doctors in improving patient treatment by combining existing information with new research.

KEYWORDS: Uterine fibroids, leiomyomas, myomas, pathogenesis, diagnosis, management, genetics, hormonal imbalances, imaging techniques, pharmacological treatments, surgical interventions.

INTRODUCTION

Uterine fibroids are benign (non-cancerous) tumors that arise from the smooth muscle cells of the uterus. They are sometimes referred to as leiomyomas or myomas. These growths are usually hard and spherical, and their diameters range widely from microscopic to several centimeters. The uterine wall, the uterine cavity, or the surface of the uterus can all host uterine fibroids, which can form as a single nodule or in clusters.^[1,2]

Uterine fibroids are benign, yet their effects on a woman's health and quality of life can be profound. Menstrual discomfort, mental misery, and anemia can result from symptoms including excessive bleeding, pelvic pain, and reproductive problems. Infertility and pregnancy problems are also frequently caused by fibroids, which adds to the total strain on women's reproductive health. Comprehending the etiology, progression, diagnosis, and therapy of uterine fibroids is essential for creating efficacious therapies and enhancing the well-being of impacted females.

Global Prevalence and Incidence

- **Prevalence:** According to estimates, 20% to 80% of women will acquire uterine fibroids by the time they

are 50 years old. Uterine fibroids impact a considerable percentage of women globally.

- **Incidence:** In 2019, there were around 241.18 uterine fibroids per 100,000 women worldwide, according to the age-standardized rate (ASR) for this condition. Compared to 1990, this indicates a rise of around 6.87%. Each region has a different incidence rate; high and high-middle sociodemographic index (SDI) regions have greater rates than low SDI regions.

Prevalence and Incidence in India

- **Prevalence:** According to reports, the prevalence of uterine fibroids in South Asia, which includes India, is around 292.19 per 100,000 women.
- **Incidence:** With an age-standardized incidence rate of about 234.42 per 100,000 women in 2019, South Asia has a higher incidence rate of uterine fibroids than the world average. This suggests that the area faces a substantial public health burden.^[3,4,5]

TYPES^[6,7]

Type of Fibroid	Location	Characteristics
Intramural Fibroids	Within the muscular wall	Most common type, can grow larger
Subserosal Fibroids	Outer wall of the uterus	Can grow large, extend outward into pelvic cavity
Submucosal Fibroids	Under the lining of the uterus	Less common, may cause significant symptoms
Pedunculated Fibroids	Attached by a stalk or peduncle	Can be subserosal or submucosal, may twist causing pain
Cervical Fibroids	Cervical tissue	Rare, may cause urination issues, labor difficulties
Interligamentous (Broad Ligament) Fibroids	Broad ligaments	Rare, can lead to complications like urinary retention

ETIOPATHOGENESIS

The intricate interaction of genetic, hormonal, and environmental variables is responsible for the etiopathogenesis of uterine fibroids.

1. Genetic Factors

- **Genetic Predisposition:** Fibroids tend to run in families, which may indicate a genetic basis for the condition. The exact genes that contribute to the formation of fibroid still need to be studied.
- **Genetic Mutations:** Although the precise processes underlying some genetic mutations or variations may increase susceptibility to fibroids, they are not entirely known.

2. Hormonal Factors

- **Estrogen and Progesterone:** These hormones are essential for the formation of fibroid tissue. Progesterone encourages fibroid cell survival and differentiation, whereas estrogen drives fibroid cell multiplication.
- **Hormonal Receptors:** Compared to normal uterine muscle cells, fibroids express larger quantities of progesterone and estrogen receptors, which increases their sensitivity to these hormones.
- **Hormonal Fluctuations:** Fibroid growth rates can be impacted by variations in hormone levels during the reproductive years, during pregnancy, or during hormonal therapy.

3. Cellular and Molecular Changes

- **Increased Cell Proliferation:** Estrogen promotes the development of fibroid cells, which increases the number of cells that divide and proliferate.
- **Extracellular Matrix (ECM) Production:** Fibroid cells overproduce ECM proteins, which results in the development of the thick, fibrous tissue mass that is specific to fibroids.
- **Angiogenesis:** To give nutrition and oxygen and assist the formation of new blood vessels, fibroids initiate angiogenesis.

4. Environmental and Lifestyle Factors

- **Dietary Factors:** Consuming a lot of red meat and little fruit, vegetable, or dairy products has been linked to an increased risk of fibroid tumors.
- **Obesity:** Estrogen produced by adipose tissue may encourage the formation of fibroids.
- **Environmental Exposures:** While precise agents and processes are yet unknown, exposure to several environmental chemicals and pollutants may have a role in the development of fibroid tumors.

5. Inflammatory and Immune Responses

- **Inflammatory Mediators:** Fibroid cell proliferation and extracellular matrix (ECM) formation are influenced by inflammatory cytokines and mediators, which may contribute to fibroid development.
- **Immune Cell Involvement:** Through cytokine production and interactions with fibroid cells, immune cells within fibroid tissues may influence fibroid development.

6. Growth and Expansion

- **Submucosal and Intramural Growth:** Fibroids can develop subserosally, which is an outward extension of the uterus, or intraamural, which is a growth within the uterine wall.
- **Size and Symptoms:** Growth rates of fibroids vary; some stay tiny and asymptomatic, while others get large enough to produce symptoms like pelvic discomfort, pressure feelings, or heavy monthly flow.

It becomes clearer why fibroids form and expand in different ways in different people when these diverse elements are taken into account. Depending on the size, location, and symptoms brought on by fibroids, treatment strategies frequently focus on hormone control, symptom management, or surgery.^[8,9,10]

SYMPTOMS AND SIGNS^[11,12]

Symptoms and Signs	Description
Heavy Menstrual Bleeding	Excessive or prolonged menstrual bleeding, often leading to anemia.
Pelvic Pain or Pressure	Dull ache or heaviness in the pelvis, sometimes accompanied by pressure on organs.
Abdominal Enlargement	Increase in abdominal size or bloating, especially with larger fibroids.
Urinary Symptoms	Frequent urination, difficulty emptying the bladder, or urinary urgency.
Constipation or Rectal Pressure	Difficulty with bowel movements or sensation of pressure on the rectum.
Painful Intercourse	Discomfort or pain during sexual intercourse (dyspareunia).
Infertility or Pregnancy Complications	Difficulty conceiving or increased risk of pregnancy complications.
Back Pain	Lower back pain that may be associated with fibroid size or location.
Leg Pain or Swelling	Rarely, fibroids pressing on nerves or blood vessels can cause leg symptoms.

DIAGNOSIS

1. Medical History and Physical Examination

- **Symptom Assessment:** Discussing symptoms like heavy menstrual bleeding, pelvic discomfort, or urinary problems is known as symptom assessment.
- **Medical History:** Finding out about reproductive history (pregnancies, miscarriages), as well as family history of fibroids.
- **Physical Examination:** Palpation of the abdomen to feel for abnormalities or an enlarged uterus; assessment of the ovaries' location and size via pelvic examination

2. Imaging Studies

- **Ultrasound:** The first imaging modality to see the uterus and find fibroids is frequently transvaginal or abdominal ultrasound. It aids in figuring out the quantity, size, and location of fibroids.
- **MRI (Magnetic Resonance Imaging):** Offers more accurate information regarding the size, location, and features of fibroid tumors by providing comprehensive pictures of the uterus and surrounding tissues. MRI is especially helpful for surgical intervention planning.

3. Other Diagnostic Tests (if indicated)

- **Hysterosalpingography (HSG):** This procedure helps identify submucosal fibroids by outlining the uterus and fallopian tubes with the use of a contrast dye injected into the uterus.
- **Hysteroscopy:** A technique in which the uterus is directly seen and submucosal fibroids are detected by inserting a narrow, illuminated telescope (hysteroscope) through the cervix into the uterus.
- **Endometrial Biopsy:** Occasionally carried out, particularly if endometrial cancer is a concern, to rule out alternative reasons of irregular uterine bleeding.

4. Differential Diagnosis

- **Adenomyosis:** A disorder that resembles fibroids in that it causes tissue that ordinarily borders the uterus to expand into the muscular walls of the uterus.
- **Endometrial Polyps:** Abnormal bleeding may result from endometrial tissue overgrowths inside the uterus.
- **Ovarian Tumors:** Some ovarian cysts or tumors might resemble fibroids in their symptoms.

5. Laboratory Tests

- **Complete Blood Count (CBC):** If there is significant monthly bleeding, a CBC test may be required to check for anemia.
- **Hormone Tests:** To assess the impact of hormones on fibroid growth, it is occasionally necessary to measure levels of hormones such as progesterone, estrogen, and thyroid hormones.^[13,14,15]

TREATMENT

The size and location of the fibroids, the intensity of the symptoms, the desire for future conception, and general health are some of the variables that determine how to treat uterine fibroids.

1. Watchful Waiting and Lifestyle Modifications

- **Monitoring:** Small, asymptomatic fibroids may not need treatment right away, but they still need to be checked on a regular basis.
- **Lifestyle Changes:** Stress management, a balanced diet, and regular exercise can all help reduce symptoms and possibly even stop the growth of fibroids.

2. Medications

- **Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):** Provide relief from period cramps and pelvic discomfort.

- **Hormonal Therapy**
- **Birth Control Pills:** Lessen severe bleeding and regulate menstrual periods.
- **Progesterone-Releasing Intrauterine Device (IUD):** An intrauterine device (IUD) that releases progesterone may be able to lessen severe bleeding.
- **Gonadotropin-Releasing Hormone (GnRH) Agonists:** Reduce fibroids temporarily by causing a menopause-like condition; however, long-term usage is not recommended owing to adverse effects and the possibility of bone loss.
- **Selective Progesterone Receptor Modulators (SPRMs):** Reduce fibroids and relieve symptoms.

3. Minimally Invasive Procedures

- **Uterine Artery Embolization (UAE):** Reduces fibroids by obstructing blood supply to them
- **MRI-Guided Focused Ultrasound Surgery (MRgFUS):** This technique heats and destroys fibroid tissue using focused ultrasound waves.
- **Myomectomy:** Surgically removing fibroids from the uterus without damaging it; frequently advised for women hoping to get pregnant in the future.

4. Surgical Procedures

- **Hysterectomy:** The last option for treating fibroids, this procedure involves surgically removing the uterus. In cases of severe symptoms or when alternative therapies are unsuitable or inefficient, it could be advised.

5. Endometrial Ablation

- **Endometrial Ablation:** This method does not treat fibroids directly; instead, it destroys the uterine lining to lessen monthly flow. Women with excessive bleeding and tiny fibroids who do not wish to become pregnant in the future are usually the ones who use it.

6. Experimental and Emerging Therapies

- **Radiofrequency Ablation (RFA):** This technique uses the heat produced by radiofrequency radiation to kill fibroid tissue.
- **High-Intensity Focused Ultrasound (HIFU):** HIFU, or high-intensity focused ultrasound, is a technique that employs ultrasound waves to ablate fibroids, much as MRgFUS.

Considerations

- **Individualized Approach:** A woman's symptoms, desire for future fertility, and general health should all be taken into consideration while making treatment selections.
- **Multidisciplinary Care:** A team approach including reproductive specialists, gynecologists, and interventional radiologists may be helpful in difficult instances.
- **Follow-up:** If fibroids are treated conservatively or with medication, frequent monitoring is crucial.^[16 to 20]

S.no	Examples	Mechanism of Action
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	Ibuprofen, Naproxen	Reduce prostaglandin synthesis, which helps alleviate pelvic pain and menstrual cramps.
Hormonal Therapy		
- Birth Control Pills	Combined oral contraceptives	Regulate menstrual cycles, reduce menstrual bleeding, and may help control fibroid growth through hormonal regulation.
- Progesterone-Releasing Intrauterine Device (IUD)	Levonorgestrel-releasing IUD (e.g., Mirena)	Releases progesterone locally in the uterus, reducing menstrual bleeding and potentially shrinking fibroids.
- Gonadotropin-Releasing Hormone (GnRH) Agonists	Leuprolide, Goserelin	Induce a temporary menopause-like state by suppressing estrogen and progesterone production, leading to fibroid shrinkage.
- Selective Progesterone Receptor Modulators (SPRMs)	Ulipristal acetate	Blocks progesterone receptors in fibroid cells, reducing their size and symptoms.
Tranexamic Acid		Inhibits fibrinolysis and reduces menstrual bleeding, used adjunctively for heavy bleeding associated with fibroids.

FUTURE DIRECTIONS AND RESEARCH IN UTERINE FIBROIDS

The field of uterine fibroids is now investigating several promising avenues to enhance comprehension, identification, and therapeutic approaches.

1. Genetic and Molecular Studies

- Studies are still looking for certain genetic mutations and changes linked to the formation of fibroid

tumors. These findings might be used to predict therapy susceptibility and inform individualized care plans. To create tailored treatments, researchers are examining the molecular processes connected to the formation of fibroid tumors and hormone responsiveness.

2. Non-Invasive Imaging Techniques

- **Improved MRI Techniques:** Using cutting-edge MRI technology to evaluate fibroid vascularity, describe fibroids more accurately, and direct less invasive procedures like MR-guided focused ultrasound (MRgFUS). Creating high-resolution ultrasound methods that enable precise fibroid monitoring and diagnosis.

3. Medical Therapies

- Creating progesterone receptor modulators (SPRMs) and other hormonal medicines with enhanced safety and effectiveness characteristics. Researching methods for delivering drugs locally to maximize therapeutic impact and reduce systemic negative effects.

4. Minimally Invasive and Surgical Techniques

- To enhance surgical results and shorten recuperation periods, more robotic-assisted surgeries are being performed for hysterectomy and myomectomy. Investigating cutting-edge fibroid treatment methods including radiofrequency ablation (RFA) and cryoablation.

5. Fertility Preservation

- Assessing the safety and effectiveness of treatments that preserve fertility while treating fibroids, such as myomectomy and uterine artery embolization (UAE). To improve management approaches, research is being done on how fibroids affect infertility, miscarriage rates, and pregnancy problems.

6. Patient-Centered Outcomes

- Carrying out in-depth research to comprehend how fibroids affect quality of life and creating patient-reported outcome measures (PROMs) for more effective symptom control. Encouraging patients and healthcare professionals to collaborate on treatment decisions in order to match objectives and preferences.

7. Health Disparities and Access to Care

- Examining differences in the frequency, diagnosis, and treatment accessibility of fibroid disorders according to racial/ethnic background, socioeconomic position, and place of residence. Using policy proposals and advocacy campaigns, removing obstacles to prompt diagnosis and treatment.

8. Long-Term Follow-Up and Recurrence

- To improve patient care and follow-up procedures, long-term outcomes and recurrence rates are monitored after various treatment methods. Creating predictive models to pinpoint patients who are more likely to experience a fibroid recurrence and customize monitoring plans for after treatment.

Improvements in these fields might lead to better patient outcomes, better management of uterine fibroids, and eventually less suffering from this prevalent gynecological ailment. To advance fibroid research and care, researchers, medical professionals, and advocacy groups must continue to collaborate.^[21 to 25]

CONCLUSION

To sum up, this comprehensive review has explored the various facets of uterine fibroids, including their etiology, pathophysiology, diagnosis, and treatment options. Benign tumors originating from the smooth muscle cells of the uterus, known as uterine fibroids, are a major global health problem for women. Clarifying the complicated pathophysiology of fibroids requires an understanding of the various elements, such as genetic predisposition, hormonal effects, and environmental factors, that contribute to their formation. The diagnosis of endometrial biopsies and hormonal assays, as well as imaging methods like MRI and ultrasound, are frequently used with clinical examination to make the diagnosis of uterine fibroids. A precise diagnosis not only validates the existence and attributes of fibroids but also directs treatment choices that are customized to meet the specific requirements of each patient.

The spectrum of management techniques includes more intrusive choices like surgical interventions and innovative minimally invasive procedures, as well as more conservative ones like careful waiting and medication regimens targeted at symptom control. Every strategy must take into account variables including the intensity of the patient's symptoms, patient age, desire for future conception, and general health state, underscoring the significance of an individualized treatment plan. Prospective studies on the biology and genetics of fibroid tumors provide promise for the advancement of personalized medicine techniques and the creation of tailored treatments. For women with uterine fibroids, improving patient education and awareness as well as ongoing multidisciplinary collaboration among healthcare professionals can further maximize outcomes and quality of life.

REFERENCES

1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. *BJOG*, 2017 Sep; 124(10): 1501-1512.
2. Afshan Bano, Calvin R Wei, Ayesha Abdul Qadir Memon, Muhammad Osama, Shumaila Shaikh, Qararo Shah, Dua Rabel, & Fahad Jibrán Siyal. (2023). A COMPREHENSIVE REVIEW OF UTERINE FIBROIDS: PATHOGENESIS, DIAGNOSIS, TREATMENT, AND FUTURE PERSPECTIVES. *Journal of Population Therapeutics and Clinical Pharmacology*, 30(18): 1961–1974.

3. Cheng LC, Li HY, Gong QQ, Huang CY, Zhang C, Yan JZ. Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study. *Front Med (Lausanne)*, 2022 Nov 7; 9: 1003605.
4. Millien C, Manzi A, Katz AM, Gilbert H, Smith Fawzi MC, Farmer PE, et al.. Assessing burden, risk factors, and perceived impact of uterine fibroids on women's lives in rural Haiti: implications for advancing a health equity agenda, a mixed methods study. *Int J Equity Health*, 2021; 20: 1.
5. Li B, Wang F, Chen L, Tong H. Global epidemiological characteristics of uterine fibroids. *Archives of Medical Science*, 2023; 19(6): 1802-1810. doi:10.5114/aoms/171786.
6. Uterine fibroids (leiomyomas): Epidemiology, clinical features
<https://www.uptodate.com/contents/uterine-fibroids-leiomyomas-epidemiology-clinical-features-diagnosis-and-natural-history>
7. Fibroids: Causes, symptoms, treatment, and types
<https://www.medicalnewstoday.com/articles/151405>
8. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. *Environ Health Perspect*, 2003 Jun; 111(8): 1037-54.
9. Alali, O. M., & Churnosov, M. I. (2023). The etiopathogenesis of uterine leiomyomas: A review. *Gynecology*, 25(1): 22-30.
10. Ciavattini A, Di Giuseppe J, Stortoni P, Montik N, Giannubilo SR, Litta P, Islam MS, Tranquilli AL, Reis FM, Ciarmela P. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. *Obstet Gynecol Int*, 2013; 2013: 173184.
11. Uterine fibroids - Symptoms and causes
<https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/syc-20354288>
12. Kaushal A, Gupta DPD, Kumar A, Clinicopathological profile of uterine fibroid at a medical college hospital. *Trop J Pathol Microbiol*, 2020; 6(2): 155-160.
13. De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. *Am Fam Physician*, 2017 Jan 15; 95(2): 100-107.
14. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. *Obstet Gynecol*, 2004; 104(2): 393-406.
15. Practice Committee of American Society for Reproductive Medicine; Society of Reproductive Surgeons. Myomas and reproductive function. *Fertil Steril*, 2008; 90(5 suppl): S125-S13.
16. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, Al-Hendy A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. *Endocr Rev*, 2022 Jul 13; 43(4): 678-719.
17. Ciebiera M, Ali M, Prince L, et al. The evolving role of natural compounds in the medical treatment of uterine fibroids. *J Clin Med*, 2020; 9(5): 1479.
18. Alfini P, Bianco V, Felice R, Magro B. [Treatment of uterine fibroma with goserelin]. *Ann Ostet Ginecol Med Perinat*, 1991; 112(6): 359-367.
19. Brunengraber LN, Jayes FL, Leppert PC. Injectable *Clostridium histolyticum* collagenase as a potential treatment for uterine fibroids. *Reprod Sci*, 2014; 21(12): 1452-1459.
20. Fischer K, McDannold NJ, Tempany CM, Jolesz FA, Fennessy FM. Potential of minimally invasive procedures in the treatment of uterine fibroids: a focus on magnetic resonance-guided focused ultrasound therapy. *Int J Womens Health*, 2015 Nov 13; 7: 901-12.
21. Taylor DK, Holthouser K, Segars JH, Leppert PC. Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management. *F1000Res*, 2015 Jul 6; 4(F1000 Faculty Rev): 183.
22. Vafaei S, Ciebiera M, Omran MM, Ghasroldasht MM, Yang Q, Leake T, Wolfe R, Ali M, Al-Hendy A. Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). *International Journal of Molecular Sciences*, 2023; 24(21): 15972.
23. Machado-Lopez A, Simón C, Mas A. Molecular and Cellular Insights into the Development of Uterine Fibroids. *International Journal of Molecular Sciences*, 2021; 22(16): 8483.
24. Guo XC, Segars JH. The impact and management of fibroids for fertility: an evidence-based approach. *Obstet Gynecol Clin North Am*, 2012 Dec; 39(4): 521-33.
25. Riggan KA, Stewart EA, Balls-Berry JE, Venable S, Allyse MA. Patient Recommendations for Shared Decision-Making in Uterine Fibroid Treatment Decisions. *Journal of Patient Experience*, 2021; 8.